Leon A S, Hunninghake D B, Belcher J, Stoulil J
Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55455.
Am J Med. 1989 Jan 23;86(1B):36-40. doi: 10.1016/0002-9343(89)90127-7.
Preliminary results are presented for the first 13 patients to complete an ongoing crossover study comparing the effects of prazosin and propranolol on blood pressure control, in which blood lipid profiles were monitored. The study population consisted predominantly of white men (mean age, 67.5 years) with mild-to-moderate hypertension and coexisting hypercholesterolemia (mean plasma cholesterol level, 244 mg/dl). Both agents resulted in statistically significant reductions in diastolic blood pressure. It is recognized that with prazosin use, there are generally no adverse changes noted between pre- and post-treatment lipid levels. The results of this study demonstrated a 243.5 mg/dl total cholesterol level at baseline and 229.5 mg/dl maintenance levels following prazosin treatment. In contrast, the results following propranolol treatment showed a tendency to increase plasma levels of triglycerides and very low-density lipoprotein cholesterol, and to reduce levels of high-density lipoprotein cholesterol and high-density lipoprotein2 cholesterol. Because of a great deal of variability in lipid responsiveness to the study drug, none of the above changes attained statistical significance. Additional data from this ongoing study are required to confirm these preliminary observations.
本文呈现了一项正在进行的交叉研究中首批13例完成患者的初步结果。该研究比较了哌唑嗪和普萘洛尔对血压控制的影响,并监测了血脂情况。研究人群主要为患有轻至中度高血压和并存高胆固醇血症(平均血浆胆固醇水平为244mg/dl)的白人男性(平均年龄67.5岁)。两种药物均使舒张压有统计学意义的降低。已知使用哌唑嗪时,治疗前后血脂水平通常无不良变化。本研究结果显示,哌唑嗪治疗前总胆固醇水平为243.5mg/dl,维持水平为229.5mg/dl。相比之下,普萘洛尔治疗后的结果显示甘油三酯和极低密度脂蛋白胆固醇血浆水平有升高趋势,高密度脂蛋白胆固醇和高密度脂蛋白2胆固醇水平有降低趋势。由于对研究药物的血脂反应存在很大变异性,上述变化均未达到统计学意义。需要来自这项正在进行的研究的更多数据来证实这些初步观察结果。